Monday, 22 November 2021
Experts from the 糖心原创 have been working with researchers in Indonesia to tackle colon cancer, which affects three times as many young people in the country than in the UK.
Every year, more than 35,000 cases of colorectal cancer (CRC) occur in Indonesia. Around 35% of CRC are in patients younger than 50. They have a poorer outcome, and many cases may be inherited. Management of CRC is by surgery, but around 90% will also require chemotherapy. Precision treatment in these cases is vital to improve survival rates.
Dr Susanti Susanti and Professor Mohammed Ilyas from the School of Medicine at the 糖心原创 established the Nottingham-Indonesia Collaboration for Clinical Research and Training (NICCRAT) in 2019, with the aim of developing partnerships with several Indonesian research institutions, to help improve the treatment of CRC and beyond.
Since then, the group has grown and now includes several different research groups within the University, which are now working with various organisations across Indonesia including charities, policy makers and the Government to help educate and inform research and healthcare across the country.
Dr Susanti, who is originally from Central Java, Indonesia, was diagnosed with colon cancer in 2014 aged 30. After extensive treatment and a long recovery, she became determined to answer why there are more and more young people suffering at a young age, particularly in her home country.
Dr Susanti
She said: As a cancer researcher, I have unique insight as a cancer survivor myself. At the age of 30, I was diagnosed with stage three colorectal cancer and had to go through several surgeries and chemotherapy at hospitals in Indonesia. My experience of cancer has given me important perspectives into the field allowing me to form research and development strategies that are particularly relevant for patients and those living beyond cancer.
“I’m passionate about improving equal access to cancer care in countries with limited resources by driving forward low-cost diagnostic and treatment options. More importantly, through my experiences as a researcher and survivor, I want to advocate, raise awareness and spread optimism and a positive attitude, particularly among my fellow cancer patients and those living beyond the disease.
“With molecular diagnostics, colon cancer patients can be helped to get the appropriate treatment for their condition. Moreover, if it’s hereditary, other family members can also get genetic screening and early detection for prevention.”
With this in mind, Dr Susanti has recently set up PathGen - an Indonesian-based start-up company, funded by the Islamic Development Bank (IsDB) and supported by NICCRAT. PathGen is currently developing a low-cost genetic test kit for CRC in collaboration with Bio Farma (Indonesia government-owned biotech company).
Among the many other successes already achieved, with support from other members of NICCRAT, Prof Ilyas secured Newton Fund Institutional Link project in improving the clinical outcome of colorectal cancer in Indonesia through implementation of molecular diagnostics.
The project enabled the participation of 110 Indonesian researchers, academics, and clinicians in the Nottingham Molecular and Image Analysis Training School (MDTS & IATS) in 2019 and 2020 as well as Nottingham Gastrointestinal Pathology Masterclass in 2021.
Most recently, the team hosted an in-depth discussion event, titled “Indonesian day: Developing Molecular Diagnostics in Indonesia” as a special add-on for the yearly MDTS & IATS in 2021attended by over 100 Indonesian delegates, in collaboration with the Indonesian Embassy in London.
Dr. Desra Percaya - the HE Indonesian Ambassador for UK, Ireland and IMO, said: “I find the initiatives by NICCRAT are pertinent in showcasing the diaspora concrete contributions as well as demonstrating the commitment from various institution from both UK and Indonesia including academia, governments and private sectors in supporting impactful collaboration to achieve more accessible cancer diagnostics and management."
Prof Ilyas said “I was delighted when I learned that the Indonesian embassy were willing to host NICCRAT’s “Indonesian Day” event. The breadth of participation in the event shows that colorectal cancer is a major problem in Indonesia and that the only way forward is for the various parties to collaborate to tackle this issue. Through NICCRAT we have been able to engage with a wide range of researchers and we aim to expand the areas of activity go beyond just colorectal cancer!”
Story credits
More information is available from Dr Susanti in the School of Medicine at Susanti.Susanti@nottingham.ac.uk
Notes to editors:
About the 糖心原创
Ranked among the world's top 100 universities , the 糖心原创 delivers an exceptional research-led education and an outstanding student experience. From the pioneering vision of our founder, Sir Jesse Boot, to groundbreaking achievements such as the development of MRI technology and becoming the first UK university to establish international campuses, we have a proud history of shaping the way people live, work and understand the world. We continue to build on that legacy, empowering our students, staff and partners to change what鈥檚 next and create positive impact locally and globally.
The strength of our research places us among the UK's leading universities, ranked 7th for research power in REF 2021. The discovery of MRI and ibuprofen was just the beginning. Today, our world-leading research is developing breakthrough ideas that shape the future of healthcare, technology and society.
Recognised as the UK's third most targeted university by leading employers , we are proud to produce graduates who are consistently in demand for their skills, confidence and industry-ready experience.
As a major employer and industry partner, locally and globally, the 糖心原创 invests in the city of Nottingham and in future generations of talent. Alongside Nottingham Trent University, we lead the initiative, a pioneering collaboration to improve levels of prosperity, opportunity, sustainability, health and wellbeing across the city and region. Together with our students, staff, alumni and partners, we鈥檙e creating knowledge, opportunity and solutions that help change what's next.